Prognostic and predictive markers in glioblastoma and ALK overexpression

Jang-Hee Kim

doi:10.4132/jptm.2021.04.29

Articles

Page Path: HOME > J Pathol Transl Med > Volume 55(3); 2021 > Article

Editorial Prognostic and predictive markers in glioblastoma and ALK overexpression: Jang-Hee Kim^,; Journal of Pathology and Translational Medicine 2021;55(3):236-237.
DOI: https://doi.org/10.4132/jptm.2021.04.29
Published online: May 13, 2021

Departments of Pathology, Ajou University School of Medicine, Suwon, Korea

Corresponding Author: Jang-Hee Kim, MD Department of Pathology, Ajou University School of Medicine, 206 World cup-ro, Yeongtong-gu, Suwon 16499, Korea Tel: +82-31-219-5925, Fax: +82-31-219-5934, E-mail: drjhk@ajou.ac.kr

• Received: April 27, 2021 • Accepted: April 29, 2021

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

3,053 Views
92 Download
4 Web of Science
5 Crossref
5 Scopus

Full Article

Download PDF

NOTES
REFERENCES

Glioblastoma (GBM) is the most common primary malignant brain tumor with a lethal clinical course [1]. Due to recent advances in medical knowledge and treatment modalities, survival of cancer patients has significantly improved. However, prognosis of patients with GBM remains dismal and less than 5% survive more than 5 years despite aggressive surgical resection and concurrent and adjuvant chemoradiation therapy [1-3]. This is the reason why new therapeutic approaches are urgently needed.

In this issue, Elsers et al. [4] reported anaplastic lymphoma kinase (ALK) and telomerase reverse transcriptase (TERT) expression in GBM and their clinical significance. The authors found ALK overexpression significantly correlated with ALK gene alterations and TERT expression. In addition, ALK and TERT overexpression and ALK gene alterations were associated with poor overall survival (OS) and progression-free survival (PFS), indicating that ALK overexpression could be an additional prognostic marker of GBM.

In GBM patients, age, performance status, extent of surgery, and histologic grade are generally considered prognostic factors [1]. With recent advances in the understanding of molecular pathogenesis of gliomas, certain molecular characteristics of gliomas have been included as prognostic markers [2,5]. Among those molecular alterations, isocitrate dehydrogenase (IDH) mutation status is considered as an important prognostic marker for GBM [1,2,5]. IDH mutation is typically identified in secondary GBM, which develops from a pre-existing glioma through malignant transformation. Patients with IDH-mutant GBM are younger and have a significantly longer survival than patients with IDH-wild type GBM [1,2]. IDH is an enzyme involved in the tricarboxylic acid cycle. IDH mutations alter enzymatic activity resulting in production of the oncometabolite, 2-hydroxyglutarate, which can cause tumor-driving epigenetic changes [6]. To date, a target agent for mutant IDH is not available. However, the development of therapies specific for IDH mutations will lead to a fundamental change in the treatment of GBM [5].

The blood brain barrier (BBB) is a major obstacle in the development of new drugs for brain tumors. Most chemotherapeutic drugs cannot penetrate the BBB and only a limited number of drugs can be used in treatment of GBM [3,5]. Temozolomide, an alkylating agent that can penetrate the BBB, is currently included in the standard GBM therapy [1,3,5]. Temozolomide induces alkylation or methylation of DNA frequently at the N⁷- or O⁶-position of guanine residues, which causes cytotoxicity and death of tumor cells. However, tumor cells with O⁶-methylguanine-DNA methyltransferase (MGMT) can remove the DNA alkyl group induced by temozolomide, rendering tumor cells resistant to temozolomide [3]. Therefore, MGMT activity status in GBM is considered an important predictive marker of therapeutic effects caused by alkylating agents. Methylation in the promoter region of MGMT can abolish MGMT activity; therefore, analysis of the methylation status in the promoter region of MGMT is currently performed in GBM patients to predict the response to temozolomide [1-3,5].

ALK is a protein with tyrosine kinase activity and encoded by the ALK gene located on chromosome 2 [7]. ALK gene alterations can promote carcinogenesis [8] and have been reported in various tumors, including anaplastic large cell lymphoma [9], melanoma [8], neuroblastoma [10], and a subset of non-small cell lung carcinoma [11]. The most frequent ALK-related genetic aberrations are translocations [12]. In recent studies, ALK overexpression in GBM reportedly ranged from 30%–70% [4,12,13]. Chiba et al. [14] suggested a possible biological role of ALK in stimulating proliferation and neovascularization in GBM. Dalia et al. [4] showed that ALK overexpression in GBM was significantly associated with proliferation of tumor cells, poor OS, and PFS, indicating a prognostic role in GBM. However, data on the prognostic role of ALK in GBM are very limited and remain controversial [4,12,13]. To properly evaluate the prognostic role of ALK in GBM, further investigative studies with large cohorts are needed.

Chemotherapeutic agents targeting ALK genetic alterations (e.g., EML4-ALK gene fusion) have been used in clinical practice for treatment of ALK-positive lung cancer and patients showed improved OS and PFS [15]. In GBM, pre-clinical and in vivo studies showed positive outcomes with application of ALK inhibitors in GBM [16-19]. To date, no clinical trials of ALK inhibitors for the treatment of GBM have shown a significant effect on the survival of GBM patients, probably due to low BBB penetration of ALK inhibitors and difficulties in achieving adequate therapeutic concentration in the brain [13,16-19]. However, development of new ALK inhibitors that can penetrate the BBB is ongoing, and if ALK overexpression can predict sensitivity to new ALK inhibitors, ALK overexpression will be an additional important predictive marker in the treatment of GBM.

Ethics Statement

Not applicable.

Availability of Data and Material

Data sharing not applicable to this article as no datasets were generated or analyzed during the study.

Code Availability

Not applicable.

Conflicts of Interest

J.-H.K., a contributing editor of the Journal of Pathology and Translational Medicine, was not involved in the editorial evaluation or decision to publish this article.

Funding Statement

No funding to declare.

REFERENCES

1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. WHO classification of tumours of the central nervous system. Revised 4th. Lyon: IARC Press, 2016; 28-56. Article
2. Eckel-Passow JE, Lachance DH, Molinaro AM, et al. Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med 2015; 372: 2499-508. Article PubMed PMC
3. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352: 997-1003. Article PubMed
4. Elsers D, Temerik DF, Attia AM, Hadia A, Hussien MT. Prognostic role of ALK-1 and h-TERT expression in glioblastoma multiforme: correlation with ALK gene alterations. J Pathol Transl Med 2021; 55: 212-224. Article PubMed PMC
5. Aldape K, Zadeh G, Mansouri S, Reifenberger G, von Deimling A. Glioblastoma: pathology, molecular mechanisms and markers. Acta Neuropathol 2015; 129: 829-48. Article PubMed
6. Gross S, Cairns RA, Minden MD, et al. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med 2010; 207: 339-44. Article PubMed PMC
7. Morris SW, Naeve C, Mathew P, et al. ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin’s lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK). Oncogene 1997; 14: 2175-88. Article PubMed
8. Wiesner T, Lee W, Obenauf AC, et al. Alternative transcription initiation leads to expression of a novel ALK isoform in cancer. Nature 2015; 526: 453-7. Article PubMed PMC
9. Yu R, Chen G, Zhou C, et al. Extra copies of ALK gene locus is a recurrent genetic aberration and favorable prognostic factor in both ALK-positive and ALK-negative anaplastic large cell lymphomas. Leuk Res 2012; 36: 1141-6. Article PubMed
10. Janoueix-Lerosey I, Lopez-Delisle L, Delattre O, Rohrer H. The ALK receptor in sympathetic neuron development and neuroblastoma. Cell Tissue Res 2018; 372: 325-37. Article PubMed
11. Wu SG, Kuo YW, Chang YL, et al. EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR. J Thorac Oncol 2012; 7: 98-104. Article PubMed
12. Karagkounis G, Stranjalis G, Argyrakos T, et al. Anaplastic lymphoma kinase expression and gene alterations in glioblastoma: correlations with clinical outcome. J Clin Pathol 2017; 70: 593-9. Article PubMed
13. Franceschi E, De Biase D, Di Nunno V, et al. The clinical and prognostic role of ALK in glioblastoma. Pathol Res Pract 2021; 221: 153447.Article PubMed
14. Chiba R, Akiya M, Hashimura M, et al. ALK signaling cascade confers multiple advantages to glioblastoma cells through neovascularization and cell proliferation. PLoS One 2017; 12: e0183516.Article PubMed PMC
15. Shaw AT, Bauer TM, de Marinis F, et al. First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. N Engl J Med 2020; 383: 2018-29. Article PubMed
16. Goodwin CR, Rath P, Oyinlade O, et al. Crizotinib and erlotinib inhibits growth of c-Met(+)/EGFRvIII(+) primary human glioblastoma xenografts. Clin Neurol Neurosurg 2018; 171: 26-33. Article PubMed
17. Greish K, Jasim A, Parayath N, et al. Micellar formulations of crizotinib and dasatinib in the management of glioblastoma multiforme. J Drug Target 2018; 26: 692-708. Article PubMed
18. Das A, Cheng RR, Hilbert ML, et al. Synergistic effects of crizotinib and temozolomide in experimental FIG-ROS1 fusion-positive glioblastoma. Cancer Growth Metastasis 2015; 8: 51-60. Article PubMed PMC
19. Le Rhun E, Chamberlain MC, Zairi F, et al. Patterns of response to crizotinib in recurrent glioblastoma according to ALK and MET molecular profile in two patients. CNS Oncol 2015; 4: 381-6. Article PubMed PMC

Figure & Data

References

Citations

Citations to this article as recorded by

Tumor markers in non-small cell lung cancer spine metastasis: an assessment of prognosis and overall survival
Brian Foresi, Aakash Shah, Seth Meade, Ajit Krishnaney
European Spine Journal.2024;[Epub] CrossRef
Extracellular Vesicle-Based Characterization of Stem Cell Phenotype in Glioblastomas
Georgiana M Serban, Manu Doina, Rodica Balasa, Adrian F Balasa
Cureus.2024;[Epub] CrossRef
CAR T-cells to treat brain tumors
Grace Guzman, Karolina Pellot, Megan R. Reed, Analiz Rodriguez
Brain Research Bulletin.2023; 196: 76. CrossRef
ALK fusions in the pan-cancer setting: another tumor-agnostic target?
Aditya Shreenivas, Filip Janku, Mohamed A. Gouda, Hui-Zi Chen, Ben George, Shumei Kato, Razelle Kurzrock
npj Precision Oncology.2023;[Epub] CrossRef
Glioblastoma multiforme targeted delivery of docetaxel using bevacizumab-modified nanostructured lipid carriers impair in vitro cell growth and in vivo tumor progression
Leonardo Delello Di Filippo, Jonatas Lobato Duarte, Juliana Hofstätter Azambuja, Rubia Isler Mancuso, Marcela Tavares Luiz, Victor Hugo Sousa Araújo, Ingrid Delbone Figueiredo, Lucas Barretto-de-Souza, Rafael Miguel Sábio, Estela Sasso-Cerri, Amanda Marti
International Journal of Pharmaceutics.2022; 618: 121682. CrossRef

PubReader
ePub Link

Cite this Article

Cite this Article: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Prognostic and predictive markers in glioblastoma and ALK overexpression

J Pathol Transl Med. 2021;55(3):236-237. Published online May 13, 2021

DOI: https://doi.org/10.4132/jptm.2021.04.29

XML Download

Related articles

Prognostic role of ALK-1 and h-TERT expression in glioblastoma multiforme: correlation with ALK gene alterations

Prognostic and predictive markers in glioblastoma and ALK overexpression